NICE has recommended a new treatment option for women with resistant ovarian cancer, marking the first new NHS treatment in more than 20 years for this group of patients. The guidance, published on 4 June 2026, gives the green light to a targeted therapy designed to find a specific protein on the surface of cancer cells and deliver medicine directly to them.
The decision is a significant step for women whose cancer has stopped responding to earlier treatment, a situation that has long left few options available through the NHS. NICE said the treatment can help people live longer and aims to improve care for those facing a difficult diagnosis.
A targeted approach for a hard-to-treat cancer
The drug works by seeking out a protein found on cancer cells and delivering a cancer-killing medicine straight to those cells. NICE’s announcement describes it as the first new NHS treatment for resistant ovarian cancer in over two decades, underscoring how limited the therapeutic landscape has been for this disease.
According to NHS England, there are around 7,500 new diagnoses of ovarian cancer each year in the UK. The latest recommendation is therefore expected to affect a meaningful number of patients who have already gone through standard treatment pathways and now need another option.
Why the announcement matters for the NHS
For clinicians, the guidance offers a new tool in a cancer area where treatment choices have historically been narrow. For patients, it brings fresh hope that a more personalised approach may extend life and provide another line of defence after previous therapies have failed.
The recommendation also reflects the continued move within UK cancer care toward targeted medicines that focus on the biology of a tumour rather than relying only on broader chemotherapy approaches. In this case, the emphasis is on precision delivery to cancer cells, which is intended to make treatment more effective for the right patients.
The guidance adds to a run of recent NHS cancer updates, but this one stands out because of how long women with resistant ovarian cancer have waited for a new approved option. With the publication now in place, the next step will be implementation across the NHS so eligible patients can access the treatment in practice.
For women and families affected by ovarian cancer, the announcement offers a notable shift: after more than 20 years without a new NHS treatment in this setting, the system now has a fresh option backed by NICE. That makes the guidance not just a policy update, but a potentially important change in everyday care.
Sources: NICE News Articles, NHS England
